Price Alert

Fusion Pharmaceuticals In... (FUSN)

NASDAQ: FUSN · Real-Time Price · USD

21.55

0.03 (0.14%)

At close: Jun 03, 2024, 10:00 PM

Fusion Pharmaceuticals Statistics

Share Statistics

Fusion Pharmaceuticals has 85.06M shares outstanding. The number of shares has increased by 0% in one year.

Shares Outstanding	85.06M
Shares Change (YoY)	0%
Shares Change (QoQ)	0%
Owned by Institutions (%)	n/a
Shares Floating	61.58M
Failed to Deliver (FTD) Shares	600
FTD / Avg. Volume	0.03%

Short Selling Information

The latest short interest is 3.04M, so 0% of the outstanding shares have been sold short.

Short Interest	3.04M
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.48

Valuation Ratios

The PE ratio is -6.64 and the forward PE ratio is -13.55. Fusion Pharmaceuticals's PEG ratio is 0.24.

PE Ratio	-6.64
Forward PE	-13.55
PS Ratio	304.9
Forward PS	165.6
PB Ratio	2.83
P/FCF Ratio	-7.36
PEG Ratio	0.24

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Fusion Pharmaceuticals.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 15.01, with a Debt / Equity ratio of 0.23.

Current Ratio	15.01
Quick Ratio	15.01
Debt / Equity	0.23
Debt / EBITDA	-0.51
Debt / FCF	-0.59
Interest Coverage	-19.21

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$20.48K
Profits Per Employee	$-939.57K
Employee Count	101
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	787K
Effective Tax Rate	-0.84%

Stock Price Statistics

The stock price has increased by 0% in the last 52 weeks. The beta is -0.69, so Fusion Pharmaceuticals's price volatility has been lower than the market average.

Beta	-0.69
52-Week Price Change	n/a
50-Day Moving Average	21.4
200-Day Moving Average	10.51
Relative Strength Index (RSI)	69.06
Average Volume (20 Days)	1,965,984

Income Statement

In the last 12 months, Fusion Pharmaceuticals had revenue of 2.07M and earned -94.9M in profits. Earnings per share was -1.45.

Revenue	2.07M
Gross Profit	723K
Operating Income	-99.23M
Net Income	-94.9M
EBITDA	-97.89M
EBIT	-88.94M
Earnings Per Share (EPS)	-1.45

Full Income Statement

Balance Sheet

The company has 61.92M in cash and 50.33M in debt, giving a net cash position of 11.59M.

Cash & Cash Equivalents	61.92M
Total Debt	50.33M
Net Cash	11.59M
Retained Earnings	-376.76M
Total Assets	323.81M
Working Capital	200.16M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -81.8M and capital expenditures -3.89M, giving a free cash flow of -85.69M.

Operating Cash Flow	-81.8M
Capital Expenditures	-3.89M
Free Cash Flow	-85.69M
FCF Per Share	-1.31

Full Cash Flow Statement

Margins

Gross margin is 34.96%, with operating and profit margins of -4798.45% and -4588.83%.

Gross Margin	34.96%
Operating Margin	-4798.45%
Pretax Margin	-4550.77%
Profit Margin	-4588.83%
EBITDA Margin	-4733.41%
EBIT Margin	-4798.45%
FCF Margin	-4143.71%

Dividends & Yields

FUSN does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

Currently there are no analyst rating for FUSN.

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	11.39
Piotroski F-Score	3